Penumbra (NYSE:PEN) Rating Lowered to Hold at Baird R W

Penumbra (NYSE:PEN) was downgraded by investment analysts at Baird R W from a “strong-buy” rating to a “hold” rating in a research note issued on Friday,Zacks.com reports.

Other analysts also recently issued research reports about the company. Wall Street Zen downgraded Penumbra from a “buy” rating to a “hold” rating in a research report on Saturday. BTIG Research lowered shares of Penumbra from a “buy” rating to a “neutral” rating and set a $349.00 price target for the company. in a report on Thursday. Evercore ISI reissued an “outperform” rating and set a $340.00 price target on shares of Penumbra in a research report on Monday, January 5th. Piper Sandler cut shares of Penumbra from an “overweight” rating to a “hold” rating and set a $374.00 price objective on the stock. in a research report on Thursday. Finally, Citigroup downgraded shares of Penumbra from a “buy” rating to a “neutral” rating and upped their price objective for the company from $350.00 to $374.00 in a research note on Thursday. Seven equities research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $355.88.

Penumbra Price Performance

Penumbra stock opened at $350.93 on Friday. The stock has a market cap of $13.74 billion, a price-to-earnings ratio of 83.95, a PEG ratio of 2.14 and a beta of 0.71. The company has a quick ratio of 4.18, a current ratio of 6.73 and a debt-to-equity ratio of 0.02. The business has a 50-day simple moving average of $303.54 and a 200 day simple moving average of $269.52. Penumbra has a 52 week low of $221.26 and a 52 week high of $352.15.

Penumbra (NYSE:PEN) last released its earnings results on Wednesday, November 5th. The company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.07. The business had revenue of $354.69 million for the quarter, compared to analysts’ expectations of $340.77 million. Penumbra had a return on equity of 11.35% and a net margin of 12.30%.The firm’s revenue was up 17.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.85 earnings per share. On average, research analysts forecast that Penumbra will post 3.67 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Penumbra news, EVP Johanna Roberts sold 1,800 shares of the business’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $300.06, for a total value of $540,108.00. Following the completion of the transaction, the executive vice president owned 64,736 shares of the company’s stock, valued at approximately $19,424,684.16. The trade was a 2.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Arani Bose sold 15,000 shares of the firm’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $308.82, for a total transaction of $4,632,300.00. Following the sale, the director directly owned 258,462 shares in the company, valued at approximately $79,818,234.84. The trade was a 5.49% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 34,144 shares of company stock valued at $10,260,127. Insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Penumbra

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. lifted its holdings in shares of Penumbra by 1,139.3% during the 2nd quarter. Invesco Ltd. now owns 633,485 shares of the company’s stock valued at $162,571,000 after buying an additional 582,369 shares during the period. Norges Bank purchased a new stake in Penumbra during the second quarter valued at $114,014,000. Holocene Advisors LP bought a new position in Penumbra in the third quarter valued at about $78,585,000. Qube Research & Technologies Ltd bought a new position in Penumbra in the second quarter valued at about $53,818,000. Finally, Man Group plc grew its stake in shares of Penumbra by 1,862.2% during the 2nd quarter. Man Group plc now owns 206,461 shares of the company’s stock valued at $52,984,000 after purchasing an additional 195,939 shares during the period. Hedge funds and other institutional investors own 88.88% of the company’s stock.

Penumbra News Summary

Here are the key news stories impacting Penumbra this week:

• Positive Sentiment: Boston Scientific agreed to acquire Penumbra for $374 per share in a cash-and-stock deal, citing strategic expansion into mechanical thrombectomy and neurovascular markets — the transaction creates a significant takeover premium that lifted investor interest. Boston Scientific announces agreement to acquire Penumbra, Inc.
• Positive Sentiment: Penumbra issued preliminary Q4 and FY2025 results/guidance showing higher-than-consensus Q4 revenue guidance (~$383.0M–$384.8M vs. $361.9M consensus) and FY revenue around $1.4B — these operational beats support the deal valuation and the company’s growth profile. Penumbra provides preliminary update on Q4 and FY2025 results
• Neutral Sentiment: Wells Fargo cut its rating to Equal Weight but left a $374 price target — the target essentially aligns with the deal price, implying limited upside beyond the acquisition terms unless a competing bid emerges. Penumbra downgraded at Wells Fargo
• Neutral Sentiment: Market commentary and earnings-estimate revisions note strong recent volume and a large one-day surge; analysts point to momentum but caution on sustainability absent competing bids or further fundamentals. Zacks coverage of Penumbra price move
• Negative Sentiment: Needham downgraded Penumbra from Buy to Hold — a straightforward analyst reaction that could weigh on sentiment and aftermarket buying absent a higher competing bid. Penumbra downgraded at Needham
• Negative Sentiment: Multiple shareholder law firms (Kahn Swick & Foti, Halper Sadeh, Ademi, Brodsky & Smith, others) have opened investigations and class-action alerts alleging the sale price/process may be unfair — litigation or legal challenges could delay the deal, lead to renegotiation, or increase transaction costs. Kahn Swick & Foti investor alert on Penumbra sale

Penumbra Company Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.